We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Provention (PRVB) Up on Deal With Sanofi for Diabetes Drug
Read MoreHide Full Article
Shares of Provention Bio, Inc. gained 25.7% after the company announced it has entered into a co-promotion agreement with pharma giant Sanofi (SNY - Free Report) ’s U.S. unit for the launch of the former’s lead investigational drug candidate teplizumab.
Teplizumab is an anti-CD3 monoclonal antibody that is being developed for the delay of clinical type 1 diabetes (T1D) in at-risk individuals, as indicated by the presence of two or more T1D-related autoantibodies.
The agreement will enable Provention Bio to use Sanofi’s expertise, capabilities and commercial resources to support the potential launch of teplizumab. The candidate is currently under review by the FDA for the above-mentioned indication with a user fee goal date of Nov 17, 2022.
Per the terms, Provention will leverage Sanofi’s in-market infrastructure and established expertise in endocrinology to expand reach, increase awareness and drive T1D screening. Sanofi will commit commercial resources in the United States, including diabetes field specialists, account directors, field-based reimbursement and medical science liaisons to expand the number of key healthcare professionals reached in the United States. On the other hand, Provention will reimburse field force-related expenses that Sanofi will incur in connection with commercializing teplizumab under the agreement. The rights for teplizumab and responsibility for the commercialization strategy, however, remain with Provention.
Provention also receives $20 million non-refundable payment granting Sanofi exclusive right of the first negotiation to in-license teplizumab globally for T1D. Sanofi can exercise until Jun 30, 2023, with an option to extend within 2023 under certain conditions.
Both companies have also entered into a Securities Purchase Agreement whereby Sanofi will purchase $35 million of the company's common stock at a premium over the daily volume-weighted average per share price for the five consecutive trading days prior to the closing date upon a potential FDA approval of teplizumab. The closing date will be at Provention's discretion and would occur no later than Feb 16, 2023.
Shares of Provention gained 24.4% in the year so far against the industry’s decline of 25.8%.
Image Source: Zacks Investment Research
The potential approval and the successful commercialization of the drug will be a significant boost for the company.
Provention is currently also evaluating teplizumab in patients with newly diagnosed insulin-dependent T1D (the phase III PROTECT study).
Loss estimates for BOLT have narrowed to $2.25 from $2.87 in the past 60 days. Earnings surpassed estimates in three of the trailing four quarters and missed the mark in the remaining one, the average beat being 2.39%.
Dynavax’s earnings estimates have increased to $1.73 from $1.14 for 2022 over the past 60 days. Earnings of DVAX surpassed estimates in two of the trailing four quarters and missed the mark in the remaining two, the average beat being 70.57%.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Provention (PRVB) Up on Deal With Sanofi for Diabetes Drug
Shares of Provention Bio, Inc. gained 25.7% after the company announced it has entered into a co-promotion agreement with pharma giant Sanofi (SNY - Free Report) ’s U.S. unit for the launch of the former’s lead investigational drug candidate teplizumab.
Teplizumab is an anti-CD3 monoclonal antibody that is being developed for the delay of clinical type 1 diabetes (T1D) in at-risk individuals, as indicated by the presence of two or more T1D-related autoantibodies.
The agreement will enable Provention Bio to use Sanofi’s expertise, capabilities and commercial resources to support the potential launch of teplizumab. The candidate is currently under review by the FDA for the above-mentioned indication with a user fee goal date of Nov 17, 2022.
Per the terms, Provention will leverage Sanofi’s in-market infrastructure and established expertise in endocrinology to expand reach, increase awareness and drive T1D screening. Sanofi will commit commercial resources in the United States, including diabetes field specialists, account directors, field-based reimbursement and medical science liaisons to expand the number of key healthcare professionals reached in the United States. On the other hand, Provention will reimburse field force-related expenses that Sanofi will incur in connection with commercializing teplizumab under the agreement. The rights for teplizumab and responsibility for the commercialization strategy, however, remain with Provention.
Provention also receives $20 million non-refundable payment granting Sanofi exclusive right of the first negotiation to in-license teplizumab globally for T1D. Sanofi can exercise until Jun 30, 2023, with an option to extend within 2023 under certain conditions.
Both companies have also entered into a Securities Purchase Agreement whereby Sanofi will purchase $35 million of the company's common stock at a premium over the daily volume-weighted average per share price for the five consecutive trading days prior to the closing date upon a potential FDA approval of teplizumab. The closing date will be at Provention's discretion and would occur no later than Feb 16, 2023.
Shares of Provention gained 24.4% in the year so far against the industry’s decline of 25.8%.
Image Source: Zacks Investment Research
The potential approval and the successful commercialization of the drug will be a significant boost for the company.
Provention is currently also evaluating teplizumab in patients with newly diagnosed insulin-dependent T1D (the phase III PROTECT study).
Zacks Rank & Stocks to Consider
Provention currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the biotech sector are Bolt Pharmaceuticals (BOLT - Free Report) and Dynavax (DVAX - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Loss estimates for BOLT have narrowed to $2.25 from $2.87 in the past 60 days. Earnings surpassed estimates in three of the trailing four quarters and missed the mark in the remaining one, the average beat being 2.39%.
Dynavax’s earnings estimates have increased to $1.73 from $1.14 for 2022 over the past 60 days. Earnings of DVAX surpassed estimates in two of the trailing four quarters and missed the mark in the remaining two, the average beat being 70.57%.